A Phase 2 Randomized, Open Label Clinical Trial in High Risk Percutaneous Coronary Intervention (PCI) Patients Receiving Standard Antithrombotic Treatment Plus Either ALX-0081 or GPIIb/IIIa Inhibitor (ReoPro) Over a Period of 24 Hours.

Trial Profile

A Phase 2 Randomized, Open Label Clinical Trial in High Risk Percutaneous Coronary Intervention (PCI) Patients Receiving Standard Antithrombotic Treatment Plus Either ALX-0081 or GPIIb/IIIa Inhibitor (ReoPro) Over a Period of 24 Hours.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Aug 2014

At a glance

  • Drugs Abciximab; Caplacizumab
  • Indications Angina pectoris; Coronary stent thrombosis; Myocardial infarction; Unstable angina pectoris
  • Focus Adverse reactions
  • Sponsors Ablynx
  • Most Recent Events

    • 18 Jul 2012 Company added in the association field as reported by EudraCT.
    • 14 Nov 2011 Status changed from active, no longer recruiting to completed.
    • 02 May 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top